Skip to Content

Patrick A. Zweidler-McKay, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Section Chief for Pediatric Leukemia and Lymphoma, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor with Tenure, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Bio Statement

My interests are in developing targeted therapies for children with leukemias and neuroblastoma and providing the latest therapies in a safe, family-centered environment.
         Clinically, I specialize in treating children with particularly difficult or relapsed forms of leukemia and lymphoma, such as infant ALL and T-cell leukemia/lymphoma. I help children get access to the latest Phase I therapies and provide hope and comfort regardless of the outcome.
         The research in my laboratory is directed at understanding the critical pathways that contribute to leukemia and neuroblastoma. We are developing a wide range of therapies targeting Notch, RET, TRK, energy production (glycolysis), metastasis and tumor vessel formation (CXCR4), etc. In collaboration we also target EGFR in neuroblastoma, Notch signaling in osteosarcoma and Ewing’s sarcoma, and we expand cord blood stem cells and natural killer cells for novel transplant approaches. Our successes have opened first-in-children studies here at M. D. Anderson Cancer Center.

UT Graduate School of Biomedical Sciences website:

Office Address

Children's Cancer Hospital at The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 853
Houston, TX 77030

Education & Training

Degree-Granting Education

1997 Temple University, Philadelphia, PA, MD, Medicine
1997 Temple University, Philadelphia, PA, PHD, Molecular Biology and Genetics
1989 Swarthmore College, Swarthmore, PA, BA, Biology

Postgraduate Training

7/2003-6/2004 Senior Fellow, Oncology Research, Children's Hospital of Philadelphia, Philadelphia, PA
7/2000-6/2003 Fellowship, Pediatric Hema. & Onc., Children's Hospital of Philadelphia, Philadelphia, PA
7/1997-6/2000 Residency, Clinical Fellow in Pediatrics, Harvard Medical School, Boston, MA
7/1997-6/2000 Residency, Pediatrics, Massachusetts General Hospital, Boston, MA

Board Certifications

11/2004 American Board of Pediatrics, Pediatric Hematology/Oncology
2000 American Board of Pediatrics


Other Appointments/Responsibilities

Member, Educational Needs Assessment & Strategic Planning Committee, The American Society of Pediatric Hematology & Oncology, Glenview, IL, 2015-present
Elected Member, Nominating Committee, The American Society of Pediatric Hematology & Oncology, Glenview, IL, 2015-present
Co-PI. A Phase II Study of the Combination of Ruxolitinib or Dasatinib with Chemotherapy in Patients with Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL), The University of Texas MD Anderson Cancer Center, Houston, TX, 2015-present
Co-chair, Working Group 1, Provost’s Physician-Scientist Assessment Taskforce, University of Texas MD Anderson Cancer Center, Houston, TX, 2014-present
Full Member, Clinical Oncology (CONC) Study Section, National Institutes of Health, Bethesda, MD, 2014
Committee Member, AALL1231: Phase III Randomized Trial Investigating Bortezomib (PS-341, Velcade) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LL) NCT021129, Children's Oncology Group, Monrovia, CA, 9/2013-present
Member, Physician-Scientist Selection Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-present
Member, National Research Council Review Committee – National Toxicology Program RoC on Formaldehyde and Leukemia, National Academies, Washington, DC, 2013-present
Ad Hoc Member, Clinical Oncology (CONC) Study Section, National Institutes of Health, Bethesda, MD, 2012
Member, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present
Member, Cancer Biology Program, University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2011-present
Member, ASPHO Program Committee, American Society of Pediatric Hematology Oncology, Glenview, IL, 2011-present
Chair, Young Investigators Committee, Children's Oncology Group, Arcadia, CA, 2011-2013
National Co-Chair, AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia, NCT01142427, Children's Oncology Group, Arcadia, CA, 2010-present
Vice-Chair, Professional Development Committee, American Society of Pediatric Hematology and Oncology, Glenview, IL, 2010-present
Member, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present
Pediatric Section Editor, CANCER, American Cancer Society Journal, Atlanta, GA, 2010-present
Editorial Board Member, ISRN Hematology Journal, Nasr City, Egypt, 2010-2013
Member, National Research Council Expert Review Committee - IRIS Assessment on Formaldehyde and Leukemia, National Academies, Washington, DC, 2010-2011
Board Member, Pfizer Hematology Advisory Board, New York, NY, 2010
National Vice Chair, ADVL0919: A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia,NCT01236586, Children's Oncology Group, Arcadia, CA, 2009-present
Local Study Chair, ADVL04P2: Phase I/II Study of Epratuzumab for Relapsed ALL, Children's Oncology Group, NCT00098839, Children's Oncology Group, Arcadia, CA, 2008-present
Acute Lymphoblastic Leukemia Committee, Children's Oncology Group, Arcadia, CA, 2008-present
Member, Young Investigator's Committee, ALL Liaison, Children's Oncology Group, Arcadia, CA, 2008-2013
ALL Molecular Risk Classifier Task Force, Children's Oncology Group, Arcadia, CA, 2008-2009
Hematologic Malignancies Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-present
High Risk ALL Study Task Force, Children's Oncology Group, Arcadia, CA, 2007-2008

Institutional Committee Activities

Member, MDACC Physician-Scientist Program Selection Committee, 2013-present
Member, Provost’s Faculty Mentoring Advisory Committee, 2008-present
Member, Children's Cancer Hospital Pediatric Support Care Committee, 2008-present
Member, American Cancer Society - Institutional Research Grant Committee, 2008-2010
Member, Flow Cytometry & Cellular Imaging Core Facility Committee, 7/2007-present
Member, Institutional Research Grant Committee, 2005-2008

Honors and Awards

2005 Physician-Scientist Award, The University of Texas M.D. Anderson Cancer Center
2004 Young Investigator Travel Award, ASPHO
2003 Young Investigator Award, American Society of Pediatric Hematology & Oncology
2000 Excellence in Teaching Award, Cambridge Hospital

Professional Memberships

American Medical Association Medical Student Section (AMA-MSS)
Judge, Resident and Fellow Section Research Symposium, 11/2009
American Society of Hematology, Washington, DC
Member, 2005-present
Children's Oncology Group, Arcadia, CA
Member, 2005-present
Harris County Medical Society, Houston, TX
Member, 2007-present
Texas Medical Society, Austin, TX
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE, Zweidler-McKay P, Amin HM, Nagarajan L.. Requirement for Ssbp2 in Hematopoietic Stem Cell Maintenance and Stress Response. Journal of Immunology, 09-2014. In Press. PMID: 25238756.
2. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood pii: blood-2015-01-607366. e-Pub 3/2015. PMID: 25778529.
3. Kellner J, Li S, Zweidler-McKay PA, Shpall EJ, McNiece I. Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations. Cytotherapy 17(4). e-Pub 12/2014. PMID: 25532425.
4. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I2, Zweidler-Mckay P, Miller L, Wolpe S, Blazar BR, Shpall EJ. Ex vivo fucosylation of 3rd party human regulatory T cells enhances anti-graft versus host disease potency in vivo. Blood 125(9). e-Pub 11/2014. PMID: 25428215.
5. Ma H, Mallampati S, Lu Y, Sun B, Wang E, Leng X, Gong Y, Shen H, Yin CC, Jones D, Amin HM, You MJ, Zweidler-McKay P, Ma Y, Kantarjian HM, Arlinghaus RB, Glassman A, Sun X. The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica(10):1591-8, 10/2014. PMCID: PMC4181255.
6. Hernandez Tejada FN, Galvez Silva JR, Zweidler-McKay PA. The challenge of targeting notch in hematologic malignancies. Front Pediatr(2):54, 6/2014. PMCID: PMC4051192.
7. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martin-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16(1):84-9, 1/2014. PMCID: PMC3883688.
8. Pickering CR, Zhang, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov.(7):770-81, 6/2013. NIHMSID: NIHMS473916.
9. Rabin KR, Gramatges MM, Borowitz MJ, Palla SL, Shi X, Margolin JF, Zweidler-McKay PA. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 59(3):468:74, 9/2012. PMCID: PMC3290726.
10. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, JS Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma?null (NSG) mice. Exp Hematol 40(6):445-56, 7/2012. PMCID: PMC3352960.
11. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood Cancer 58(5):682-9, 5/2012. PMCID: PMC3264695.
12. Blonska M, Joo D,Zweidler-McKay PA, Zhao Q, Lin X. CARMA1 Controls Th2 Cell-Specific Cytokine Expression through Regulating JunB and GATA3 Transcription Factors. J Immunol 188(7):3160-8, 4/2012. PMCID: PMC3311756.
13. Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Zhang X, Vannini I, Fanini F, Fabbri M, Lanza G, Reis RM, Zweidler-McKay PA, Calin GA. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology 142(4):886-896, 4/2012. e-Pub 1/2012. PMCID: PMC3321100.
14. Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs 30(1):191-9, 2/2012. e-Pub 10/2010. PMID: 20890785.
15. Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J,Zweidler-McKay PA. Notch/HES1-mediated PARP1 activation: a cell-type specific mechanism for tumor suppression. Blood 117(10):2891-2900, 3/2011. e-Pub 1/2011. PMCID: PMC3062299.
16. Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. The Selective Trk Inhibitor AZ623 Inhibits BDNF-Mediated Neuroblastoma Cell Proliferation and Signaling and is Synergistic with Topotecan. Cancer 117(6):1321-91, 3/2011. e-Pub 10/2010. PMID: 20960503.
17. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta like ligand 4 - Notch signaling regulating BM-derived pericyte/vascular smooth muscle cell formation. Blood 117(2):719-26, 1/2011. PMCID: PMC3031490.
18. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother 33(7):684-96, 9/2010. PMCID: PMC3530422.
19. Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP. Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth in vitro and in vivo. Cancer 116(13):3233-3243, 7/2010. PMCID: PMC2923448.
20. Zhang P, Yang Y, Nolo R, Zweidler-McKay PA, Hughes DP. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex1 and its role in osteosarcoma invasiveness. Oncogene 20(29):2916-26, 5/2010. e-Pub 3/2010. PMCID: PMC2874642.
21. Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler-McKay PA, Brandt SJ, Agulnick A, Nagarajan L. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene 29(21):3044-53, 5/2010. e-Pub 3/2010. PMCID: PMC2878399.
22. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 16(3):848-56, 2/2010. e-Pub 1/2010. PMCID: PMC2818539.
23. Steiner D, Gelovani J, Savoldo B, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler-McKay PA, Bollard CM, Shpall EJ, Dotti G, Simmons PJ. Noninvasive Bioluminescent Imaging Demonstrates Long-Term Multilineage Engraftment of Ex Vivo-Expanded CD34-Selected Umbilical Cord Blood Cells. Stem Cells 27(8):1932-1940, 8/2009. PMID: 19544439.
24. Thress K, MacIntyre T, Wang H, Whiston D, Liu ZY, Hoffmann E, Want T, Brown JL, Webster K, Omer C, Zage PE, Zeng L, Zweidler-McKay PA (senior author). Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8(7):1818-27, 7/2009. PMID: 19509272.
25. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal Granulocyte-Macrophage Colony Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis. Antimicrob Agents Chemother 52(2):716-8, 2008. e-Pub 11/2007. PMCID: PMC2224773.
26. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-McKay P, Ryan A, Folkman J, Ryeom S, Heymach J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7(2):418-24, 2008. e-Pub 2/2008. PMID: 18245671.
27. Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay PA, Grupp SA. Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood 111(2):705-14, 2008. e-Pub 10/2007. PMCID: PMC2200835.
28. Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN. The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by IL-2 withdrawal. Molecular and Cellular Biology 16(11):6263-6272, 1996. PMCID: PMC231629.
29. Bell DW, Taguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Gilks CB, Zweidler-McKay P, Grimes HL, Tsichlis PN, Testa JR. Chromosomal localization of a gene, GF1, encoding a novel zinc finger protein reveals a new syntenic region between man and rodents. Cytogenet Cell Genet 70(3-4):263-7, 1995. PMID: 7789186.
30. Cohen BH, Zweidler PA, Goldwein JW, Molloy J, Packer RJ. Ototoxic effect of cisplatin in children with brain tumors. Pediatric Neurosurgery 16(6):292-296, 1990. PMID: 2134738.


1. Kannan S, Hall MA, Golfman LS, Zweidler-McKay PA. Notch Signaling In B-ALL Reveals PLK1 As A Potential Therapeutic Target In B-ALL: PLK1-Selective Inhibitor Poloxin Modulates Cyclin B and P53 Pathways, Leading To Growth Arrest and Apoptosis. Blood - Poster presented at 55th ASH Annual Meeting and Exposition 12-8-13. In Press.
2. Rabin KR, Gramatges MM, Margolin JF, Zweidler-McKay PA.. Reply to "Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia". Pediatr Blood Cancer 61(1):180, 1/2014. PMID: 23956240.
3. Boston C, Fang W, Rabin K, Gramatges M, Borowitz M, Palla S, Shi X, Margolin J, Zweidler-McKay P. Patient age yields insights into absolute lymphocyte counts and T Cells in Pediatric ALL. Presented at American Society of Pediatric Hematology/Oncology 26th Annual Meeting, Miami, FL, 2013.
4. Kannan S, Zweidler-McKay P. Notch/HES1 Signaling Stabilizes p53 Expression Via a Novel PARP1-Chfr-PLK1-Mediated Mechanism in B-ALL. Poster presentation at 54th ASH Annual Meeting and Exposition in Atlanta, GA, 12/2012.
5. Zweidler-McKay PA. InviClone wars: IgH subclones in preB-ALL. Blood 120(22):4280-1, 11/2012. PMID: 23175661.
6. Boston C, Golfman L, Fang W, Zeng L, Lee D, Zweidler-McKay P. Enhancing T cell recovery following induction chemotherapy for ALL may improve survival: a role for immune-modulators?. Pediatric Blood & Cancer Special Issue: American Society of Pediatric Hematology/Oncology 25th Annual Meeting, New Orleans, LA 58(7):1041, 7/2012.
7. Zweidler-McKay, Nolo R. A study of Neuroblastoma Phenotypic Plasticity. Presented at American Society of Pediatric Hematology/Oncology 25th Annual Meeting, New Orleans, LA, 2012.
8. Zweidler-McKay P, Zeng L. Aberrant Histone H1 localization is a novel response biomarker and target for neuroblastoma. Presented at American Society of Pediatric Hematology/Oncology 25th Annual Meeting, New Orleans, LA, 2012.
9. Zweidler-McKay P, Nolo R. Ligand-mediated CIS-inhibition: A Novel Mechanism for NOTCH pathway modulation. Presented at American Society of Pediatric Hematology/Oncology 25th Annual Meeting, New Orleans, LA, 2012.
10. Kannan S, Fang W, Zweidler-McKay P. Multiple Mechanisms of Notch-Mediated B-ALL Growth Arrest Via HES1 and PLK1: KIF11, CyclinB and p53. Oral and posters abstracts at 53rd ASH Annual Meeting and Exposition, 12/2011.
11. Tsimberidou AM, Keating MJ, Estry EH, Jabbout E, Zweidler-McKay P, Plunkett W, Kantarjian HM, Borthakur G. Phase I-II Study of Fludarabine, Cytarabine and Oxaliplatin In Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Presented at Ash Meeting in Orlando Florida, 11/2011.
12. Graham C, Darwin J, Zweidler-McKay P, Kannan S, Collins-Underwood R, Mullighan C. The Sun and the Sea: Balancing Ikaros in AML, T-ALL and B-ALL. Pediatric Blood & Cancer 56(6):923-923, 6/2011.
13. Sceusi E, Rasid A, Zhou Y, Samuel S, Fan F, Xia L, Ye X-C, Lu J, Tozzi F, Gaur P, Fleming JB, Abdalla ED, Curley SA, Vauthey J-N, Zweidler-McKay P, Meyn R, Yao J, Ellis LM. Primary culture of human midgut carcinoid cell lines and isolation of a putative carcinoid stem cell population. Presented at AACR 102nd Annual Meeting, 4/2011.
14. Sceusi E, Rashid A, Zhou YF, Samuel S, Fan F, Xia L, Ye XC, Lu J, Tozzi F, Gaur P, Zweidler-McKay P, Meyn R, Yao J, Ellis LM. Methods in the Development of Human Carcinoid Cell Lines. Pancreas 40(2):331-331, 3/2011.
15. Kannan S, Fang WD, Zweidler-McKay P. NOTCH and PLK1: Targeting Novel Mechanisms in B-ALL. Pediatric Blood & Cancer 56(6):922-922, 2011.
16. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA (senior author). Absolute lymphocyte count is a novel prognostic indicator in acute leukemia: Implications for risk stratification and future studies. Cancer 112(2):407-15, 2008. PMID: 18058809.

Book Chapters

1. Zweidler-McKay PA (Co-Author). M. D. Anderson Cancer Center. In: My Child Isn't Getting Better - A Helpful Guide for Parents from Parents. M. D. Anderson Cancer Center: Houston, 2010.

Grant & Contract Support

Title: Stromal Interactions and Leukemic Risk in Myelodysplastic Syndromes
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Naora
Duration: 4/6/2015 - 3/31/2017
Title: Improving risk allocation and developing novel therapies for children with T-ALL
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: David T. Teachey
Duration: 4/1/2015 - 3/31/2020

Last updated: 7/20/2015